小中大
抱歉，我是这方面新手，原以为截取一句话就能说清楚了，所以随便写了个受体上去，本想只求语法通顺，因为要是从头说怕越说越复杂。现在各位朋友都说要提供更全的文字。我把里面两段放在下面了，请大家帮我看看，谢谢！
Interleukin (IL)–33 is a new member of the IL-1 family, which includes IL-18 and IL-1β. Like IL-18 and IL-1β, IL-33
was found to have strong immunomodulatory functions (1). However, whereas IL-1β and IL-18 promote
proinflammatory and TH1-associated responses, IL-33 induces the production of TH2-associated cytokines and
increased levels of serum Ig (1). Moreover, treatment of mice with IL-33 led to high levels of serum IgE and
expression of TH2-associated cytokines (1). IL-33 signals via its unique receptor, ST2, and IL-1RAcP (1, 2). ST2, also
called T1, DER4 and Fit-2, is highly expressed on mast cells and on TH2 cells (1–4).
The ST2 gene encodes two isoforms of ST2 proteins: ST2L, a transmembrane form, and the soluble ST2 (sST2), a
secreted form that can serve as a decoy receptor of IL-33. We have reported that ST2 is associated with important TH2
effector functions (4–6). Treatment of mice with either an antagonistic antibody against ST2 or with an ST2-Fc fusion
protein led to enhancement of T helper type 1 (TH1) responses and an inhibitory effect on TH2-associated allergic
airway inflammation . Interestingly, high levels of sST2 has been found in the sera of patients with acute Asthma
(7), and serum elevations of sST2 predict mortality and heart failure in patients with acute myocardial infarction (8, 9).
Moreover, a role for IL-33/ST2 has also been suggested for arthritis and atherosclerosis (10, 11). However, the role of
IL-33/ST2 in systemic anaphylactic shock (SAS or type I hypersensitivity), is unknown.
